Your session is about to expire
← Back to Search
BMSCRP1 Trial Summary
This trial will test whether it is safe to give participants with retinitis pigmentosa an injection of their own stem cells in order to improve their vision.
- Retinitis Pigmentosa
BMSCRP1 Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
BMSCRP1 Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
BMSCRP1 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there currently a recruitment period for this research experiment?
"Affirmative. As documented on clinicaltrials.gov, this medical experiment is presently accepting participants - the study was first posted on June 1st 2021 and has since been updated on September 1st 2022. 4 patients are required for one location."
How many subjects are currently engaged in this experiment?
"Affirmative. Data on clinicaltrials.gov reveals that this investigation is actively enrolling participants, with its initial post date being June 1st 2021 and the most recent update occurring September 1st 2022. The study aims to enlist 4 individuals from a single centre."
What end goals are researchers striving to achieve with this experiment?
"The primary goal of this 6-month long study is to determine the practicality of administering autologous CD34+ cells intravitreally. Other important metrics for evaluation include Electroretinography (with an emphasis on changes in "a" and "b" wave amplitude from baseline), National Eye Institute Vision Questionnaire results, and Microperimetry scores (measuring change in reduced sensitivity)."
Has the FDA sanctioned Intravitreal autologous CD34+ cells for use in treatment?
"The safety of Intravitreal autologous CD34+ cells is thought to be low, as evidenced by its rating of 1. This assessment reflects the fact that this clinical trial is in Phase 1 and there are limited data demonstrating efficacy or safety."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends